Continue to perfect your practice in LAA Closure
Watch EuroPCR 2025 sponsored scientific session to make sure you stay up to date with the 12 177 peers that joined us at the congress.
Broadening OPTIONs for LAA Closure: Innovations and Outcomes
"We now have the option to treat patients who don’t want lifelong anticoagulation — with safety and efficacy."
— Apostolos Tzikas
Explore how left atrial appendage closure (LAAC) is reshaping stroke prevention after ablation with our EuroPCR 2025 sessions on demand. A panel of international experts presents new data from the OPTION trial, showing that LAAC is non-inferior to DOACs for stroke prevention and significantly reduces long-term bleeding risk. Through expert discussion and a recorded case from Bern, the session covers practical strategies for both sequential and concomitant LAAC, the role of imaging in planning, and how the Watchman FLX Pro device supports treatment of challenging anatomies. This session offers timely insights for interventional cardiologists and electrophysiologists looking to optimise outcomes in patients with atrial fibrillation.
LAAC · OPTION TRIAL · WATCHMAN FLX · STROKE PREVENTION · LEFT ATRIAL APPENDAGE CLOSURE
Sign up to access this video and the full collection of EuroPCR 2025 sessions from Boston Scientific.
Caution:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.